Petosemtamab Shows “Clinically Meaningful Activity” in Advanced HNSCC
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Diagnosis & Disease Information
Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent or Metastatic HNSCC
Adding ipilimumab to treatment with nivolumab does not improve response or survival outcomes in recurrent/metastatic HNSCC, a phase 2 trial suggests.
Ficlatuzumab Plus Cetuximab Yields Responses in HPV-Negative HNSCC
Ficlatuzumab plus cetuximab has demonstrated antitumor activity in pan-refractory, recurrent/metastatic head and neck squamous cell carcinoma.
Patient-Clinician Identity Discordance Influences Whether Cancer Survivors Seek Care
Cancer survivors may be more likely to delay or forgo care if their treating clinician is of a different race, gender, or other identity, a new study suggests.
Adverse Birth Outcomes More Common Among AYAs With Cancer During Pregnancy
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Cancer Patients Reported Symptoms of PTSD During First Year of COVID-19 Pandemic
Patients with cancer experienced symptoms of PTSD during the first year of the COVID-19 pandemic, a French study suggests.
Classifying Oropharyngeal Cancer by p16 Status Alone Deemed Insufficient
Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests.
Social Vulnerability Tied to Worse Pediatric Head and Neck Cancer Outcomes
Increasing social vulnerability is associated with significant decreases in surveillance and survival time among pediatric patients with head and neck cancers.
Quitting Smoking Tied to Better Survival in Head and Neck Cancer
Among patients with head and neck cancer, smoking cessation for more than 10 years is associated with reduced overall mortality and cancer-specific mortality.
Docetaxel Acts as Radiosensitizer in Head and Neck Cancer
Adding docetaxel to radiation improves outcomes for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase 2/3 trial suggests.
- Loading...
Loading...
Next post in Head and Neck Cancer
Loading... 
Loading...